All News
Best of 2017: New EULAR Guidelines on Behçet's
At the EULAR 2016 meeting, new EULAR recommendations for the management of Behçet's disease (BD) were presented.
Read ArticleThe RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)
Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.
Read ArticleFive Barriers to Biosimilar Adoption in the US
A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.
Read ArticleThe RheumNow Week in Review – EULAR18 Epilogue (6.22.18)
Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.
Read ArticleCDC Obesity Prevalence Higher in the Rural USA
MMWR reports that approximately 46 million persons (14%) in the United States live in nonmetropolitan counties, where there is a higher prevalence of obesity-associated chronic diseases such as diabetes, coronary heart disease, and arthritis.
Read ArticleEULAR 2018 - Podcast from Day 4
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
You can also listen on iTunes, Soundcloud or Stitcher.
Read Article
Gout Takeaways
The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.
Read ArticleMethotrexate Update
I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.
Read ArticleEULAR 2018 - Podcast from Day 3
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
You can also listen on iTunes, Soundcloud or Stitcher.
Read Article
The RheumNow Week in Review – EULAR18 Abbreviated (6.15.18)
We're crazy busy at EULAR all week. Instead of this review, we recommend that you tune into our multiple podcasts from experts and faculty attending EULAR 2018 in Amsterdam. You can find these on iTunes, SoundCloud or Stitcher.
Read ArticleChanging my Mind at EULAR
Each year I attend I hope that I’m going to come across something that changes my practice and this year, I think I may have struck gold at a session on Giant Cell arteritis at EULAR in Amsterdam.
Read ArticleUpdate on Osteoporosis
This session was an update on the management of osteoporosis given by Professor Christian Roux from France.
Read ArticleEULAR 2018 - Day 2 Report
Highlights from Day 2 of the EULAR meeting in Amsterdam include high MBDA scores in ACPA negative RA predicts remission; characterization of difficult RA; and gender differences in psoriatic responses to TNF inhibitors.
Read ArticleEULAR 2018 - Podcast from Day 1 & 2
This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.
Read ArticleCardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA
Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides.
Read ArticleBiosimilar Data at #EULAR2018
Biosimilars are here, and more are being registered all the time, so I was really interested in the biosimilar data at the meeting.
EULAR 2018 - Day 1 Report
Highlights from the first day at EULAR include: canakinumab prevents acute gout; AS uveitis benefits from most TNFi; MRI does not improve T2Tor X-ray outcomes; baracitinib wins in SLE - maybe?; new lupus criteria; and lost survival in RA. Here's the RheumNow recap.
Read ArticleThe RheumNow Week in Review – Baricitinib Splash (6.7.18)
Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.
Read ArticleAdvance Practice Clinicians Proliferating in Specialty Practices
An analysis of SK&A outpatient provider files, covering 90% of physician practices in the United States, shows that between 2008 to 2016, there was a 22% increase in the employment of advanced practice clinicians (APCs) by specialty practices. By 2016, 28% of all specialty practices employed APCs.
Read ArticlePrescription Drug Monitoring Programs Fail to Deter Opiate Abuse
A systematic review of prescription drug monitoring programs (PDMPs), advocated in the president's Prescription Drug Abuse Prevention Plan, fails to show evidence of efficacy in preventing nonfatal and fatal overdoses.
Read Article


